



Plenary sitting

B8-0045/2017

5.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on epidermodysplasia verruciformis

Mireille D'Ornano

Motion for a European Parliament resolution on epidermodysplasia verruciformis

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas epidermodysplasia verruciformis (EV) is a rare genetic disease, 200 cases of which have been described in scientific literature, but whose prevalence is otherwise unknown; whereas it is associated with generalised human papillomavirus infections (in particular HPV-5, HPV-8, and HPV-14), causes the progressive appearance of wart-like lesions on the torso, neck, face, forearms and feet and may, in 30-60% of cases, lead to the development of cutaneous carcinomas;
- B. whereas EV is a multifactorial disease, and whereas two genes responsible for triggering it have been identified on chromosome 17;
- C. whereas immunodeficiency associated, in particular, with HIV was also identified in 2007 as a potential cause of EV;
- D. whereas the only existing treatment for EV is surgical excision of the wart-like lesions;
- 1. Calls on the Commission, through the relevant European agencies, and the Member States to support research projects on treating EV.